论文部分内容阅读
1990年6月至1991年6月选择中晚期食管癌64例,随机入卡铂加放疗组和单纯放疗组,两组放疗剂量为60～70Gy/6～7周,卡铂加放疗组,放疗第1、4周同时用卡铂,两周期总量为1000mg。卡铂加放疗组近期疗效明显优于单纯放疗组,1年生存率分别为65.6％(21/32)和40.6％(13/32),有显著差异,显示卡铂与放疗有明显协同作用。
From June 1990 to June 1991, 64 patients with advanced esophageal cancer were randomized to receive carboplatin plus radiotherapy and radiotherapy alone. The radiotherapy dose was 60 to 70 Gy/6 to 7 weeks in both groups. Carboplatin plus radiotherapy and radiotherapy were performed. Carboplatin was used in the first and fourth weeks, and the total amount of the two cycles was 1000 mg. The short-term efficacy of carboplatin plus radiotherapy group was significantly better than that of radiotherapy alone. The 1-year survival rates were 65.6% (21/32) and 40.6% (13/32), respectively. There was a significant difference, indicating that carboplatin and radiotherapy have a significant synergistic effect.